Lilly FASTens On SGX Following Shareholder Vote To Complete Acquisition
This article was originally published in The Pink Sheet Daily
Executive Summary
Lilly acquires SGX, with its “FAST” fragment-based drug discovery platform and preclinical oncology portfolio; new subsidiary can move beyond financial woes.
You may also be interested in...
Lumena Pharmaceuticals Takes $23M To Fight Rare Liver Disease
The San Diego start-up will use its Series A round to continue development on a pair of drugs for cholestatic liver disease. Once studied by Pfizer and Sanofi to fight high cholesterol but shelved years ago as statins proved more effective, the drugs show promise in orphan indications.
Pharma Thriller: Lilly Rumored To Be Mystery Bidder For ImClone
Eli Lilly is rumored to be the mystery bidder for ImClone - the latest wrinkle in an ongoing saga that pits the biotech's Chairman Carl Icahn against its marketing partner Bristol-Myers Squibb. Lilly is reportedly offering $6.1 billion for the biotech, or $70 a share, which, if true, validates Icahn's hard-line rejection of a standing offer from BMS to pay $62 a share
Pharma Thriller: Lilly Rumored To Be Mystery Bidder For ImClone
Eli Lilly is rumored to be the mystery bidder for ImClone - the latest wrinkle in an ongoing saga that pits the biotech's Chairman Carl Icahn against its marketing partner Bristol-Myers Squibb. Lilly is reportedly offering $6.1 billion for the biotech, or $70 a share, which, if true, validates Icahn's hard-line rejection of a standing offer from BMS to pay $62 a share